NeuroPace (NPCE) Cash from Investing Activities Growth (1y) (2021 - 2026)
NeuroPace (NPCE) Cash from Investing Activities Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -4,224.26% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 95.53% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | -87.14% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | -18.20% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | -208.79% |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | -397.90% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -514.25% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | -187.82% |
| 10 | NeuroPace | 517.05 Mn | 463.07 Mn | 18.05 Mn | -216.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -216.22% |
| Dec 31, 2025 | -104.95% |
| Sep 30, 2025 | -102.14% |
| Jun 30, 2025 | -105.19% |
| Mar 31, 2025 | -101.54% |
| Dec 31, 2024 | -43.45% |
| Sep 30, 2024 | -66.60% |
| Jun 30, 2024 | -38.92% |
| Mar 31, 2024 | -76.20% |
| Dec 31, 2023 | -61.02% |
| Sep 30, 2023 | -39.86% |
| Jun 30, 2023 | -35.65% |
| Mar 31, 2023 | 3,390.20% |
| Dec 31, 2022 | 5,877.92% |
| Sep 30, 2022 | 3,767.89% |
| Jun 30, 2022 | 110.29% |
| Mar 31, 2022 | 93.92% |
| Dec 31, 2021 | 98.47% |
| Sep 30, 2021 | 24.00% |
| Mar 31, 2021 | -969.00% |